Table 2.
Response | Cisplatin (n = 72) | Paclitaxel (n = 67) | Total (n = 139) |
---|---|---|---|
Responder (RCB-0/1) | 19 (26.4%) | 15 (22.3%) | 34 (24.5%) |
Non-Responder (RCB-2/3 or crossover) | 53 (73.6%) | 52 (77.6%) | 105 (75.5%) |
pCR | 11 (15.3%) | 8 (11.9%) | 19 (13.7%) |
Non-pCR | 61 (84.7%) | 59 (88.1%) | 120 (86.3%) |
Abbreviations: pCR, pathologic complete response; RCB, residual cancer burden.